Mackay Shields LLC Mirati Therapeutics, Inc. Transaction History

Mackay Shields LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$144.0 - $179.73 $1.9 Million - $2.37 Million	-13,200 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$158.92 - $221.61 $1.29 Million - $1.8 Million	-8,100 Reduced 38.03%	13,200 $2.26 Million
Q4 2020 Feb 16, 2021	SELL	$162.05 - $240.27 $291,690 - $432,486	-1,800 Reduced 7.79%	21,300 $4.68 Million
Q3 2020 Nov 04, 2020	SELL	$113.26 - $167.27 $249,172 - $367,994	-2,200 Reduced 8.7%	23,100 $3.84 Million
Q2 2020 Jul 31, 2020	BUY	$72.01 - $120.39 $518,472 - $866,808	7,200 Added 39.78%	25,300 $2.89 Million
Q1 2020 May 08, 2020	SELL	$69.78 - $116.21 $20,934 - $34,863	-300 Reduced 1.63%	18,100 $1.39 Million
Q4 2019 Feb 11, 2020	SELL	$70.76 - $128.86 $56,608 - $103,088	-800 Reduced 4.17%	18,400 $2.37 Million
Q3 2019 Nov 01, 2019	BUY	$77.91 - $109.6 $23,373 - $32,880	300 Added 1.59%	19,200 $1.5 Million
Q2 2019 Aug 13, 2019	BUY	$59.49 - $104.71 $1.12 Million - $1.98 Million	18,900 New	18,900 $1.95 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Mackay Shields LLC, based on Form 13F filings with the SEC.

Stay updated on Mackay Shields LLC with notifications on news.